Clearmind Medicine (CMND) Cash from Financing Activities (2022 - 2026)
Clearmind Medicine (CMND) posted quarterly Cash from Financing Activities of $4.6 million for Q2 2026, up 44555.07% year-over-year from N/an in Q2 2025, and down 38.28% quarter-over-quarter from $7.4 million in Q1 2026.
Clearmind Medicine (CMND) Cash from Financing Activities (2022 - 2026) Analysis & Trends
Clearmind Medicine's Cash from Financing Activities history runs 5 years deep, the most recent figure standing at $4.6 million for Q2 2026.
- In Q2 2026, Cash from Financing Activities rose 44555.07% year-over-year to $4.6 million; the TTM figure through Apr 2026 stood at $14.2 million (up 1097.99% YoY), while the FY2025 annual figure was $2.6 million, down 58.07% from the prior year.
- Cash from Financing Activities for Q2 2026 stood at $4.6 million, down from $7.4 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $580.7 billion in Q3 2022, with the low at -$580.7 billion in Q4 2022.
- The 5-year median for Cash from Financing Activities is $1.4 million (2024), against an average of $2.0 million.
- The sharpest annual moves came in 2025 and 2026: Cash from Financing Activities tumbled 107.1% in 2025, then soared 44555.07% in 2026.
- Clearmind Medicine's Cash from Financing Activities stood at -$580.7 billion in 2022, then surged by 100.0% to $2.4 million in 2023, then sank by 86.56% to $323205.0 in 2024, then jumped by 592.7% to $2.2 million in 2025, then jumped by 104.48% to $4.6 million in 2026.
- Business Quant data shows CMND's Cash from Financing Activities at $4.6 million in Q2 2026, $7.4 million in Q1 2026, and $2.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Clearmind Medicine | 537,435.54 | -13.06 Mn | - | 4.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 4.58 Mn |
| Apr 30, 2026 | 4.58 Mn |
| Jan 31, 2026 | 7.42 Mn |
| Jan 31, 2026 | 7.42 Mn |
| Oct 31, 2025 | 2.24 Mn |
| Oct 31, 2025 | 2.24 Mn |
| Jul 31, 2025 | -10,812.00 |
| Jul 31, 2025 | -10,812.00 |
| Apr 30, 2025 | -10,298.00 |
| Apr 30, 2025 | -10,298.00 |
| Jan 31, 2025 | 404,812.00 |
| Jan 31, 2025 | 404,812.00 |
| Oct 31, 2024 | 323,205.00 |
| Oct 31, 2024 | 323,205.00 |
| Jul 31, 2024 | 469,537.00 |
| Jul 31, 2024 | 469,537.00 |
| Apr 30, 2024 | 145,129.00 |
| Apr 30, 2024 | 145,129.00 |
| Jan 31, 2024 | 5.32 Mn |
| Jan 31, 2024 | 5.32 Mn |